CN1703523A - 诊断前列腺癌的方法 - Google Patents

诊断前列腺癌的方法 Download PDF

Info

Publication number
CN1703523A
CN1703523A CNA038255014A CN03825501A CN1703523A CN 1703523 A CN1703523 A CN 1703523A CN A038255014 A CNA038255014 A CN A038255014A CN 03825501 A CN03825501 A CN 03825501A CN 1703523 A CN1703523 A CN 1703523A
Authority
CN
China
Prior art keywords
prc
group
pin
composition
experimenter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CNA038255014A
Other languages
English (en)
Chinese (zh)
Inventor
中村佑辅
片桐丰雅
中川英刀
中鹤修一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
University of Tokyo NUC
Original Assignee
Oncotherapy Science Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, University of Tokyo NUC filed Critical Oncotherapy Science Inc
Publication of CN1703523A publication Critical patent/CN1703523A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038255014A 2002-09-30 2003-09-22 诊断前列腺癌的方法 Withdrawn CN1703523A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41487302P 2002-09-30 2002-09-30
US60/414,873 2002-09-30

Publications (1)

Publication Number Publication Date
CN1703523A true CN1703523A (zh) 2005-11-30

Family

ID=32069779

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038255014A Withdrawn CN1703523A (zh) 2002-09-30 2003-09-22 诊断前列腺癌的方法
CNA038253453A Pending CN1701078A (zh) 2002-09-30 2003-09-22 前列腺癌相关基因和多肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA038253453A Pending CN1701078A (zh) 2002-09-30 2003-09-22 前列腺癌相关基因和多肽

Country Status (9)

Country Link
US (1) US7521205B2 (https=)
EP (3) EP1546197A2 (https=)
JP (2) JP2006500950A (https=)
KR (2) KR20050074467A (https=)
CN (2) CN1703523A (https=)
AU (2) AU2003264881A1 (https=)
CA (2) CA2500859A1 (https=)
TW (2) TW200413539A (https=)
WO (2) WO2004031414A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101220392B (zh) * 2006-10-31 2014-06-04 维里德克斯有限责任公司 前列腺癌鉴定
CN106053815A (zh) * 2016-07-01 2016-10-26 复旦大学附属中山医院 Gpc1作为肿瘤诊断标志物的用途
CN107427552A (zh) * 2014-08-22 2017-12-01 中国科学院生物物理研究所 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN110029168A (zh) * 2019-05-09 2019-07-19 山东省立医院 基因fgl1在制备结直肠癌和肺癌诊断试剂盒的应用及试剂盒
CN111465857A (zh) * 2017-08-08 2020-07-28 昆士兰科技大学 诊断早期心力衰竭的方法
CN113358870A (zh) * 2021-05-31 2021-09-07 中国药科大学 Orm2蛋白在制备诊断区分前列腺癌和良性前列腺增生的试剂盒中的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1733047A2 (en) * 2004-02-27 2006-12-20 Oncotherapy Science, Inc. Pin-prc transition genes
US7939251B2 (en) * 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
US10066268B2 (en) * 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
US8067153B2 (en) 2005-07-27 2011-11-29 Oncotheraphy Science, Inc. Genes and polypeptides relating to prostate cancers
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
JP2007275027A (ja) * 2006-04-12 2007-10-25 Fujifilm Corp 癌関連欠失遺伝子マーカーを用いた癌の診断方法
CN101827936B (zh) 2007-08-20 2014-12-10 肿瘤疗法科学股份有限公司 Cdh3肽以及含有cdh3肽的药剂
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20130253035A1 (en) * 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
WO2015066189A2 (en) * 2013-10-29 2015-05-07 Cornell University Modification of nuclear actin by mical-2 regulates srf signaling
JP6425942B2 (ja) * 2014-08-20 2018-11-21 学校法人日本大学 前立腺癌の判定、治療選択方法、予防又は治療剤
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
CN110331156B (zh) * 2019-05-30 2021-10-12 深圳大学 抗Mical2多克隆抗体及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
ES2245778T3 (es) * 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5783435A (en) * 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
CA2372815A1 (en) * 1999-05-11 2000-11-16 Incyte Genomics, Inc. Extracellular matrix and adhesion-associated proteins
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
AU2001229340A1 (en) * 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002214576A1 (en) * 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
AU2002338265A1 (en) * 2001-03-28 2002-10-15 Incyte Genomics, Inc. Molecules for disease detection and treatment
WO2003066821A2 (en) 2002-02-04 2003-08-14 The Johns Hopkins University Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101220392B (zh) * 2006-10-31 2014-06-04 维里德克斯有限责任公司 前列腺癌鉴定
CN107427552A (zh) * 2014-08-22 2017-12-01 中国科学院生物物理研究所 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN114796497A (zh) * 2014-08-22 2022-07-29 广州英恩迈生物医药科技有限公司 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN106053815A (zh) * 2016-07-01 2016-10-26 复旦大学附属中山医院 Gpc1作为肿瘤诊断标志物的用途
CN111465857A (zh) * 2017-08-08 2020-07-28 昆士兰科技大学 诊断早期心力衰竭的方法
CN110029168A (zh) * 2019-05-09 2019-07-19 山东省立医院 基因fgl1在制备结直肠癌和肺癌诊断试剂盒的应用及试剂盒
CN110029168B (zh) * 2019-05-09 2020-02-14 山东省立医院 基因fgl1在制备结直肠癌和肺癌诊断试剂盒的应用及试剂盒
CN113358870A (zh) * 2021-05-31 2021-09-07 中国药科大学 Orm2蛋白在制备诊断区分前列腺癌和良性前列腺增生的试剂盒中的应用
CN113358870B (zh) * 2021-05-31 2022-04-05 中国药科大学 Orm2蛋白在制备诊断区分前列腺癌和良性前列腺增生的试剂盒中的应用

Also Published As

Publication number Publication date
AU2003263611A8 (en) 2004-04-23
KR20050067409A (ko) 2005-07-01
CA2500861A1 (en) 2004-04-15
EP1546197A2 (en) 2005-06-29
AU2003264881A1 (en) 2004-04-23
CA2500859A1 (en) 2004-04-15
JP2006500950A (ja) 2006-01-12
CN1701078A (zh) 2005-11-23
WO2004031231A3 (en) 2004-07-08
KR20050074467A (ko) 2005-07-18
EP1546411A2 (en) 2005-06-29
TW200418988A (en) 2004-10-01
WO2004031231A2 (en) 2004-04-15
EP2090587A1 (en) 2009-08-19
TW200413539A (en) 2004-08-01
AU2003263611A1 (en) 2004-04-23
WO2004031414A3 (en) 2004-07-08
US7521205B2 (en) 2009-04-21
WO2004031414A2 (en) 2004-04-15
US20060160991A1 (en) 2006-07-20
AU2003264881A8 (en) 2004-04-23
JP2006518186A (ja) 2006-08-10

Similar Documents

Publication Publication Date Title
CN1703523A (zh) 诊断前列腺癌的方法
US20050259483A1 (en) Genes and polypeptides relating to prostate cancers
CN1703522A (zh) 诊断睾丸精原细胞瘤的方法
CN1890382A (zh) 检测、诊断和治疗肝细胞癌(hcc)的方法
EP1549771B1 (en) Method for diagnosing pancreatic cancer
JP4579246B2 (ja) 乳癌を診断する方法
US20090162361A1 (en) Method for diagnosing pancreatic cancer
EP2305811A1 (en) Method of diagnosing smal cell lung cancer
US20110092388A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
CN1705753A (zh) 非小细胞肺癌的诊断方法
CN1695059A (zh) 诊断结肠癌和胃癌的方法
CN1882698A (zh) 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
CN102618545B (zh) 与人癌细胞的永生化相关的基因及其应用
US20080063640A1 (en) Pin-Prc Transition Genes
CN101068935A (zh) 与乳腺癌相关的基因和多肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication